Reversion of the ErbB malignant phenotype and the DNA damage response

Experimental and Molecular Pathology

Volumn 93, Issue 3, 2012, Pages 324-333

  Runkle, E Aaron ^a   Zhang, Hongtao ^a   Cai, Zheng ^a   Zhu, Zhiqiang ^a   Karger, Barry L ^b   Wu, Shiaw Lin ^b   O'Rourke, Donald M ^a   Zhou, Zhaocai ^c   Wang, Qiang ^d   Greene, Mark I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

DNA repair; Double strand breaks; EGFR; ErbB; HER; Ionizing radiation; KASH; LINC; Nuclear compartmentalization; SUN

Indexed keywords

CETUXIMAB; DNA DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; KU ANTIGEN; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CELL NUCLEUS MEMBRANE; DIMERIZATION; DNA DAMAGE; DNA RECOMBINATION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG MECHANISM; ENZYME ACTIVE SITE; ESOPHAGUS CARCINOMA; FEEDBACK SYSTEM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; MISMATCH REPAIR; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN FUNCTION; RADIOSENSITIZATION; SIGNAL TRANSDUCTION;

DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ONCOGENE PROTEINS V-ERBB; PHENOTYPE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84870680391     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2012.09.007     Document Type: Article

References (188)

1. Ahnesorg P., et al. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 2006, 124:301-313.
2. Aly A., Ganesan S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. Journal of Molecular Cell Biology 2011, 3:66-74.
3. Andres S.N., et al. Crystal structure of human XLF: a twist in nonhomologous DNA end-joining. Molecular Cell 2007, 28:1093-1101.
4. Antoniacci L.M., et al. The nuclear envelope and spindle pole body-associated Mps3 protein bind telomere regulators and function in telomere clustering. Cell Cycle 2007, 6:75-79.
5. Audeh M.W., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
6. Barker C.A., Powell S.N. Enhancing radiotherapy through a greater understanding of homologous recombination. Seminars in Radiation Oncology 2010, 20(267-273):e3.
7. Barnes D.E., et al. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Current biology: CB 1998, 8:1395-1398.
8. Baselga J., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2010, 28:1138-1144.
9. Bassing C.H., et al. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:8173-8178.
10. Baumann P., West S.C. DNA end-joining catalyzed by human cell-free extracts. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14066-14070.
11. Bertocci B., et al. Nonoverlapping functions of DNA polymerases mu, lambda, and terminal deoxynucleotidyltransferase during immunoglobulin V(D)J recombination in vivo. Immunity 2006, 25:31-41.
12. Block W.D., et al. Autophosphorylation-dependent remodeling of the DNA-dependent protein kinase catalytic subunit regulates ligation of DNA ends. Nucleic Acids Research 2004, 32:4351-4357.
13. Blumenschein G.R., et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29:2312-2318.
14. Blunt T., et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:10285-10290.
15. Bonner J.A., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine 2006, 354:567-578.
16. Bonner J.A., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology 2010, 11:21-28.
17. Boone J.J., et al. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Molecular Cancer Therapeutics 2009, 8:3015-3023.
18. Bozulic L., et al. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Molecular Cell 2008, 30:203-213.
19. Bupp J.M., et al. Telomere anchoring at the nuclear periphery requires the budding yeast Sad1-UNC-84 domain protein Mps3. The Journal of Cell Biology 2007, 179:845-854.
20. Burma S., et al. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. The Journal of Biological Chemistry 2001, 276:42462-42467.
21. Burma S., et al. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair 2006, 5:1042-1048.
22. Calsou P., et al. The DNA-dependent protein kinase catalytic activity regulates DNA end processing by means of Ku entry into DNA. The Journal of Biological Chemistry 1999, 274:7848-7856.
23. Caponigro F., et al. A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anti-cancer drugs 2008, 19:739-744.
24. Celeste A., et al. Genomic instability in mice lacking histone H2AX. Science 2002, 296:922-927.
25. Chan D.W., Lees-Miller S.P. The DNA-dependent protein kinase is inactivated by autophosphorylation of the catalytic subunit. The Journal of Biological Chemistry 1996, 271:8936-8941.
26. Chan D.W., et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes & Development 2002, 16:2333-2338.
27. Chen L., et al. Ataxia-telangiectasia-mutated dependent phosphorylation of Artemis in response to DNA damage. Cancer Science 2005, 96:134-141.
28. Chinnaiyan P., et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Research 2005, 65:3328-3335.
29. Contessa J.N., et al. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 1999, 5:405-411.
30. Cook P.J., et al. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 2009, 458:591-596.
31. Cortes J., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2012, 30:1594-1600.
32. Costantini S., et al. Interaction of the Ku heterodimer with the DNA ligase IV/Xrcc4 complex and its regulation by DNA-PK. DNA Repair 2007, 6:712-722.
33. Critchlow S.E., et al. Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Current Biology: CB 1997, 7:588-598.
34. Cui X., et al. Autophosphorylation of DNA-dependent protein kinase regulates DNA end processing and may also alter double-strand break repair pathway choice. Molecular and Cellular Biology 2005, 25:10842-10852.
35. Curran D., et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2007, 25:2191-2197.
36. Ding Q., et al. DNA-PKcs mutations in dogs and horses: allele frequency and association with neoplasia. Gene 2002, 283:263-269.
37. Ding Q., et al. Autophosphorylation of the catalytic subunit of the DNA-dependent protein kinase is required for efficient end processing during DNA double-strand break repair. Molecular and Cellular Biology 2003, 23:5836-5848.
38. Dittmann K., et al. Nuclear EGFR as novel therapeutic target: insights into nuclear translocation and function. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al.] 2010, 186:1-6.
39. Dominguez O., et al. DNA polymerase mu (Pol mu), homologous to TdT, could act as a DNA mutator in eukaryotic cells. The EMBO Journal 2000, 19:1731-1742.
40. Douglas P., et al. Identification of in vitro and in vivo phosphorylation sites in the catalytic subunit of the DNA-dependent protein kinase. The Biochemical Journal 2002, 368:243-251.
41. Drebin J.A., et al. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985, 41:697-706.
42. Drebin J.A., et al. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:9129-9133.
43. Drebin J.A., et al. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 1988, 2:273-277.
44. Drouet J., et al. Interplay between Ku, Artemis, and the DNA-dependent protein kinase catalytic subunit at DNA ends. The Journal of Biological Chemistry 2006, 281:27784-27793.
45. Eccles L.J., et al. Delayed repair of radiation induced clustered DNA damage: friend or foe?. Mutation Research 2011, 711:134-141.
46. Falck J., et al. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005, 434:605-611.
47. Ferguson K.M., et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Molecular Cell 2003, 11:507-517.
48. Foley J., et al. At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone 2012, Odontology / the Society of the Nippon Dental University.
49. Foray N., et al. Constitutive association of BRCA1 and c-Abl and its ATM-dependent disruption after irradiation. Molecular and Cellular Biology 2002, 22:4020-4032.
50. Franchitto A., et al. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase. Oncogene 2003, 22:2110-2120.
51. Frank K.M., et al. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature 1998, 396:173-177.
52. Fuller S.J., et al. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. Journal of Molecular and Cellular Cardiology 2008, 44:831-854.
53. Garcia-Diaz M., et al. DNA polymerase lambda, a novel DNA repair enzyme in human cells. The Journal of Biological Chemistry 2002, 277:13184-13191.
54. Garrett T.P., et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002, 110:763-773.
55. Gell D., Jackson S.P. Mapping of protein-protein interactions within the DNA-dependent protein kinase complex. Nucleic Acids Research 1999, 27:3494-3502.
56. Golding S.E., et al. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. Cancer Biology & Therapy 2009, 8:730-738.
57. Goodarzi A.A., et al. DNA-PK autophosphorylation facilitates Artemis endonuclease activity. The EMBO Journal 2006, 25:3880-3889.
58. Gottlieb T.M., Jackson S.P. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 1993, 72:131-142.
59. Graus-Porta D., et al. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Molecular and Cellular Biology 1995, 15:1182-1191.
60. Graus-Porta D., et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. The EMBO Journal 1997, 16:1647-1655.
61. Grawunder U., et al. Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature 1997, 388:492-495.
62. Grawunder U., et al. DNA ligase IV binds to XRCC4 via a motif located between rather than within its BRCT domains. Current biology: CB 1998, 8:873-876.
63. Gregoire V., et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 2011, 100:62-69.
64. Griffero F., et al. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. The Journal of Biological Chemistry 2009, 284:7138-7148.
65. Gu J., et al. XRCC4:DNA ligase IV can ligate incompatible DNA ends and can ligate across gaps. The EMBO Journal 2007, 26:1010-1023.
66. Gu J., et al. Single-stranded DNA ligation and XLF-stimulated incompatible DNA end ligation by the XRCC4-DNA ligase IV complex: influence of terminal DNA sequence. Nucleic Acids Research 2007, 35:5755-5762.
67. Gupta S., Meek K. The leucine rich region of DNA-PKcs contributes to its innate DNA affinity. Nucleic Acids Research 2005, 33:6972-6981.
68. Hagan M., et al. Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 2004, 10:5724-5731.
69. Hambardzumyan D., et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes & Development 2008, 22:436-448.
70. Hentges P., et al. Evolutionary and functional conservation of the DNA non-homologous end-joining protein, XLF/Cernunnos. The Journal of Biological Chemistry 2006, 281:37517-37526.
71. Heron D.E., et al. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. American Journal of Clinical Oncology 2011, 34:165-172.
72. Holz C., et al. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 2011, 101:158-164.
73. Horton J.K., et al. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. International Journal of Radiation Oncology, Biology, Physics 2010, 76:998-1004.
74. Huang L.C., et al. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:4827-4832.
75. Huang S.M., et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research 1999, 59:1935-1940.
76. Huang S.M., et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Research 2002, 62:4300-4306.
77. Hurt C.N., et al. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 2011, 11:466.
78. Jaspersen S.L., et al. Mps3p is a novel component of the yeast spindle pole body that interacts with the yeast centrin homologue Cdc31p. The Journal of Cell Biology 2002, 159:945-956.
79. Jaspersen S.L., et al. The Sad1-UNC-84 homology domain in Mps3 interacts with Mps2 to connect the spindle pole body with the nuclear envelope. The Journal of Cell Biology 2006, 174:665-675.
80. Jatoi A., et al. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Annals of Oncology: Official Journal of the European Society for Medical Oncology (ESMO) 2010, 21:2040-2044.
81. Jensen A.D., et al. Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer 2011, 117:2986-2994.
82. Jin S., et al. Binding of Ku and c-Abl at the kinase homology region of DNA-dependent protein kinase catalytic subunit. The Journal of Biological Chemistry 1997, 272:24763-24766.
83. Joensuu G., et al. A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. International Journal of Radiation Oncology, Biology, Physics 2010, 78:42-49.
84. Junop M.S., et al. Crystal structure of the Xrcc4 DNA repair protein and implications for end joining. The EMBO Journal 2000, 19:5962-5970.
85. Kang K.B., et al. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair. International Journal of Radiation Oncology, Biology, Physics 2012, 83:e43-e52.
86. Khanna K.K., Jackson S.P. DNA double-strand breaks: signaling, repair and the cancer connection. Nature Genetics 2001, 27:247-254.
87. Kim J.S., et al. Independent and sequential recruitment of NHEJ and HR factors to DNA damage sites in mammalian cells. The Journal of Cell Biology 2005, 170:341-347.
88. Kohda D., et al. A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor. The Journal of Biological Chemistry 1993, 268:1976-1981.
89. Kokai Y., et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 1989, 58:287-292.
90. Kokunai T., et al. Overcoming of radioresistance in human gliomas by p21WAF1/CIP1 antisense oligonucleotide. Journal of Neuro-Oncology 2001, 51:111-119.
91. Kriegs M., et al. The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. DNA Repair 2010, 9:889-897.
92. Kurimasa A., et al. Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. Molecular and Cellular Biology 1999, 19:3877-3884.
93. Lammering G., et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. Journal of the National Cancer Institute 2001, 93:921-929.
94. Lax I., et al. Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Molecular and Cellular Biology 1988, 8:1831-1834.
95. Lee K.K., et al. Lamin-dependent localization of UNC-84, a protein required for nuclear migration in Caenorhabditis elegans. Molecular Biology of the Cell 2002, 13:892-901.
96. Lees-Miller S.P., et al. Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science 1995, 267:1183-1185.
97. Lehman J.A., et al. DNA-dependent conformational changes in the Ku heterodimer. Biochemistry 2008, 47:4359-4368.
98. Lei K., et al. Inner nuclear envelope proteins SUN1 and SUN2 play a prominent role in the DNA damage response. Current Biology: CB 2012, 22:1609-1615.
99. Li Z., et al. The XRCC4 gene encodes a novel protein involved in DNA double-strand break repair and V(D)J recombination. Cell 1995, 83:1079-1089.
100. Li Y., et al. Crystal structure of human XLF/Cernunnos reveals unexpected differences from XRCC4 with implications for NHEJ. The EMBO Journal 2008, 27:290-300.
101. Liang K., et al. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular Cancer Therapeutics 2003, 2:1113-1120.
102. Lu H., et al. Length-dependent binding of human XLF to DNA and stimulation of XRCC4.DNA ligase IV activity. The Journal of Biological Chemistry 2007, 282:11155-11162.
103. Ma Y., et al. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002, 108:781-794.
104. Ma Y., et al. The DNA-dependent protein kinase catalytic subunit phosphorylation sites in human Artemis. The Journal of Biological Chemistry 2005, 280:33839-33846.
105. Ma Y., et al. The Artemis:DNA-PKcs endonuclease cleaves DNA loops, flaps, and gaps. DNA Repair 2005, 4:845-851.
106. Magnander K., Elmroth K. Biological consequences of formation and repair of complex DNA damage. Cancer Letters 2012, (Epub ahead of print).
107. Mahajan K.N., et al. Association of DNA polymerase mu (pol mu) with Ku and ligase IV: role for pol mu in end-joining double-strand break repair. Molecular and Cellular Biology 2002, 22:5194-5202.
108. Mahaney B.L., et al. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. The Biochemical Journal 2009, 417:639-650.
109. Mari P.O., et al. Dynamic assembly of end-joining complexes requires interaction between Ku70/80 and XRCC4. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:18597-18602.
110. Martin S.A., et al. Therapeutic targeting of the DNA mismatch repair pathway. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16:5107-5113.
111. Masuda Y., Kamiya K. Molecular nature of radiation injury and DNA repair disorders associated with radiosensitivity. International Journal of Hematology 2012, 95:239-245.
112. Meek K., et al. trans Autophosphorylation at DNA-dependent protein kinase's two major autophosphorylation site clusters facilitates end processing but not end joining. Molecular and Cellular Biology 2007, 27:3881-3890.
113. Merkle D., et al. The DNA-dependent protein kinase interacts with DNA to form a protein-DNA complex that is disrupted by phosphorylation. Biochemistry 2002, 41:12706-12714.
114. Minjgee M., et al. K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. International Journal of Radiation Oncology, Biology, Physics 2011, 81:1506-1514.
115. Modesti M., et al. DNA binding of Xrcc4 protein is associated with V(D)J recombination but not with stimulation of DNA ligase IV activity. The EMBO Journal 1999, 18:2008-2018.
116. Moon A.F., et al. The X family portrait: structural insights into biological functions of X family polymerases. DNA Repair 2007, 6:1709-1725.
117. Moshous D., et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001, 105:177-186.
118. Mukherjee B., et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Research 2009, 69:4252-4259.
119. Murray M.M., et al. Role played by BRCA1 in transcriptional regulation in response to therapy. Biochemical Society Transactions 2007, 35:1342-1346.
120. Nagai S., et al. Functional targeting of DNA damage to a nuclear pore-associated SUMO-dependent ubiquitin ligase. Science 2008, 322:597-602.
121. Nick McElhinny S.A., et al. Ku recruits the XRCC4-ligase IV complex to DNA ends. Molecular and Cellular Biology 2000, 20:2996-3003.
122. Nishikawa S., et al. Nep98p is a component of the yeast spindle pole body and essential for nuclear division and fusion. The Journal of Biological Chemistry 2003, 278:9938-9943.
123. No M., et al. Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biology & Therapy 2009, 8:2351-2361.
124. O'Driscoll M., et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Molecular Cell 2001, 8:1175-1185.
125. Ogiso H., et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
126. O'Rourke D.M., et al. Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:3250-3255.
127. O'Rourke D.M., et al. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:10842-10847.
128. O'Rourke D.M., et al. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly. Oncogene 1998, 16:1197-1207.
129. Oza P., et al. Mechanisms that regulate localization of a DNA double-strand break to the nuclear periphery. Genes & Development 2009, 23:912-927.
130. Park B.W., et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nature Biotechnology 2000, 18:194-198.
131. Park J., et al. DNA-dependent protein kinase-mediated phosphorylation of protein kinase B requires a specific recognition sequence in the C-terminal hydrophobic motif. The Journal of Biological Chemistry 2009, 284:6169-6174.
132. Pickhard A.C., et al. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways. BMC Cancer 2011, 11:388.
133. Pietras R.J., et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Research 1999, 59:1347-1355.
134. Poinsignon C., et al. The metallo-beta-lactamase/beta-CASP domain of Artemis constitutes the catalytic core for V(D)J recombination. The Journal of Experimental Medicine 2004, 199:315-321.
135. Portera C.C., et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:2710-2716.
136. Povirk L.F., et al. Processing of 3'-phosphoglycolate-terminated DNA double strand breaks by Artemis nuclease. The Journal of Biological Chemistry 2007, 282:3547-3558.
137. Qian X., et al. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:1500-1504.
138. Reddy Y.V., et al. Non-homologous end joining requires that the DNA-PK complex undergo an autophosphorylation-dependent rearrangement at DNA ends. The Journal of Biological Chemistry 2004, 279:39408-39413.
139. Riballo E., et al. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Current Biology: CB 1999, 9:699-702.
140. Riballo E., et al. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Molecular Cell 2004, 16:715-724.
141. Riemsma R., et al. Systematic review of lapatinib in combination with letrozole compared with other first line treatments for hormone receptor positive (HR+) and HER2+ advanced or metastatic breast cancer (MBC). Current Medical Research and Opinion 2012, 28:1263-1279.
142. Rodriguez-Rocha H., et al. DNA damage and autophagy. Mutation Research 2011, 711:158-166.
143. Roepstorff K., et al. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochemistry and Cell Biology 2008, 129:563-578.
144. Rogakou E.P., et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. The Journal of Biological Chemistry 1998, 273:5858-5868.
145. Rooney S., et al. Leaky Scid phenotype associated with defective V(D)J coding end processing in Artemis-deficient mice. Molecular Cell 2002, 10:1379-1390.
146. Schober H., et al. Yeast telomerase and the SUN domain protein Mps3 anchor telomeres and repress subtelomeric recombination. Genes & Development 2009, 23:928-938.
147. Shin E.K., et al. A kinase-negative mutation of DNA-PK(CS) in equine SCID results in defective coding and signal joint formation. Journal of Immunology 1997, 158:3565-3569.
148. Shintani S., et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. International Journal of Cancer. Journal International du Cancer 2003, 107:1030-1037.
149. Sibanda B.L., et al. Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats. Nature 2010, 463:118-121.
150. Singh N., et al. Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1. Proceedings of the National Academy of Sciences of the United States of America 2012.
151. Singleton B.K., et al. The C terminus of Ku80 activates the DNA-dependent protein kinase catalytic subunit. Molecular and Cellular Biology 1999, 19:3267-3277.
152. Skvortsova I., et al. Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 2010, 96:108-115.
153. Smyth E.C., Cunningham D. Targeted therapy for gastric cancer. Current Treatment Options in Oncology 2012, 13:377-389.
154. Soeda A., et al. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. The Journal of Biological Chemistry 2008, 283:10958-10966.
155. Solomon B., et al. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. International Journal of Radiation Oncology, Biology, Physics 2003, 55:713-723.
156. Sosa B.A., et al. LINC complexes form by binding of three KASH peptides to domain interfaces of trimeric SUN proteins. Cell 2012, 149:1035-1047.
157. Soubeyrand S., et al. Threonines 2638/2647 in DNA-PK are essential for cellular resistance to ionizing radiation. Cancer Research 2003, 63:1198-1201.
158. Soubeyrand S., et al. Artemis phosphorylated by DNA-dependent protein kinase associates preferentially with discrete regions of chromatin. Journal of Molecular Biology 2006, 358:1200-1211.
159. Starr D.A., Han M. Role of ANC-1 in tethering nuclei to the actin cytoskeleton. Science 2002, 298:406-409.
160. Stea B., et al. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Letters 2003, 202:43-51.
161. Stucki M., et al. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 2005, 123:1213-1226.
162. Suwa A., et al. DNA-dependent protein kinase (Ku protein-p350 complex) assembles on double-stranded DNA. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:6904-6908.
163. Tanaka T., et al. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:1266-1273.
164. Taylor T.E., et al. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Current Cancer Drug Targets 2012, 12:197-209.
165. Toulany M., et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clinical Cancer Research: An Official journal of the American Association for Cancer Research 2006, 12:4119-4126.
166. Toulany M., et al. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Molecular Cancer Therapeutics 2008, 7:1772-1781.
167. Toulany M., et al. ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 2010, 97:338-345.
168. Toulany M., et al. Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Molecular Cancer Research: MCR 2012, 10:945-957.
169. Tsai C.J., et al. Cernunnos/XLF promotes the ligation of mismatched and noncohesive DNA ends. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:7851-7856.
170. Tutt A., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
171. Walker J.R., et al. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 2001, 412:607-614.
172. Wallasch C., et al. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. The EMBO Journal 1995, 14:4267-4275.
173. Wang Q., et al. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. Oncogene 1998, 17:1939-1948.
174. Wang Y., et al. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes & Development 2000, 14:927-939.
175. Wang Q., et al. Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. Oncogene 2001, 20:4640-4649.
176. Wang M., et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Research 2011, 71:6261-6269.
177. Wang W., et al. Structural insights into SUN-KASH complexes across the nuclear envelope. Cell Research 2012.
178. Ward I.M., Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. The Journal of Biological Chemistry 2001, 276:47759-47762.
179. Weidhaas J.B., et al. A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans. Cancer Research 2006, 66:10434-10438.
180. Weterings E., et al. The role of DNA dependent protein kinase in synapsis of DNA ends. Nucleic Acids Research 2003, 31:7238-7246.
181. Weterings E., et al. The Ku80 carboxy terminus stimulates joining and Artemis-mediated processing of DNA ends. Molecular and Cellular Biology 2009, 29:1134-1142.
182. Yano K., Chen D.J. Live cell imaging of XLF and XRCC4 reveals a novel view of protein assembly in the non-homologous end-joining pathway. Cell Cycle 2008, 7:1321-1325.
183. Yoo S., Dynan W.S. Geometry of a complex formed by double strand break repair proteins at a single DNA end: recruitment of DNA-PKcs induces inward translocation of Ku protein. Nucleic Acids Research 1999, 27:4679-4686.
184. Zhang H.T., et al. Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells. Oncogene 1997, 14:2863-2869.
185. Zhang X., et al. Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response. Molecular and Cellular Biology 2004, 24:9207-9220.
186. Zhang X., et al. SUN1/2 and Syne/Nesprin-1/2 complexes connect centrosome to the nucleus during neurogenesis and neuronal migration in mice. Neuron 2009, 64:173-187.
187. Zhou H., et al. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. International Journal of Radiation Oncology, Biology, Physics 2004, 58:344-352.
188. Zhou Z., et al. Structure of Sad1-UNC84 homology (SUN) domain defines features of molecular bridge in nuclear envelope. The Journal of Biological Chemistry 2012, 287:5317-5326.